CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) announced FDA approval on April 16, 2026 for an expanded indication of Caldolor (ibuprofen) Injection to include management of postoperative pain in adults and pediatric patients ages 3 months and older.

The company also launched a redesigned website for healthcare professionals featuring perioperative resources, dosing, safety, and J-Code reimbursement support.

AI-generated analysis. Not financial advice.

Positive

• FDA expanded indication to include postoperative pain
• Indication covers adults and pediatric patients ≥3 months
• Website launch with perioperative resources and J-Code access support

Negative

• Contraindication for use during peri-operative period of CABG surgery
• Hypersensitivity and NSAID allergy contraindications limit eligible patients

News Market Reaction – CPIX

-3.44%

1 alert

-3.44% News Effect

-$2M Valuation Impact

$50.53M Market Cap

0.0x Rel. Volume

On the day this news was published, CPIX declined 3.44%, reflecting a moderate negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $50.53M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Pediatric indication age: 3 months and older Clinical program phase: Phase II

2 metrics

Pediatric indication age 3 months and older Caldolor indication now includes patients ages 3 months+

Clinical program phase Phase II Ifetroban programs in multiple serious conditions

Market Reality Check

Price: $4.68 Vol: Volume 54,495 is 1.11x th...

normal vol

$4.68 Last Close

Volume Volume 54,495 is 1.11x the 20-day average of 49,019, indicating slightly elevated interest ahead of this news. normal

Technical Shares at $3.20 are trading below the 200-day MA at $3.36, and sit 48.92% under the 52-week high and 72.97% above the 52-week low.

Peers on Argus

Sector peers show a mixed tape: DRRX down 1.04%, INCR down 0.93%, while RMTI and...

1 Down

Sector peers show a mixed tape: DRRX down 1.04%, INCR down 0.93%, while RMTI and CRDL are up 1.90% and 2.88%, respectively, and ASRT is flat. Momentum scanner only flags SCYX down 5.41% with no news, supporting a stock-specific read for CPIX.

Historical Context

5 past events · Latest: Mar 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 17	Brand website update	Positive	-1.6%	Launch of new Sancuso website with educational CINV resources.
Mar 4	Market research report	Neutral	-4.1%	Report on projected H. pylori infections market growth and pipeline.
Mar 3	Earnings and pipeline	Positive	-19.9%	Q4 and 2025 revenue growth with pipeline and J-code updates.
Feb 25	Talicia promotion launch	Positive	+4.6%	Start of national U.S. sales promotion for Talicia.
Feb 25	Talicia JV launch	Positive	+4.6%	Commencement of joint U.S. commercialization of Talicia with RedHill.

Pattern Detected

Recent history shows several positive operational updates (websites, promotions, revenue growth) sometimes met with negative price reactions, particularly around earnings, but commercial partnership news has coincided with gains.

Recent Company History

Over the last few months, Cumberland reported strong Q4 2025 revenue growth, expanded commercialization of Talicia, and enhanced digital resources for key brands like Sancuso. Despite Q4 revenues of $13.7M (31% growth) and full-year $44.5M, the stock dropped nearly 20% following that earnings release, while Talicia launch headlines on Feb 25 aligned with gains of about 4.6%. The current Caldolor indication expansion and website upgrade continue this pattern of brand-focused, commercialization-driven news flow.

Market Pulse Summary

This announcement highlights an FDA-approved expansion for Caldolor, adding postoperative pain manag...

Analysis

This announcement highlights an FDA-approved expansion for Caldolor, adding postoperative pain management across adults and children as young as 3 months, and pairs it with a refreshed professional website emphasizing non-opioid, multimodal perioperative care. In the broader context of recent brand and commercialization initiatives, it extends Cumberland’s hospital-acute portfolio. Investors may watch future updates on utilization trends for Caldolor, as well as progress in the company’s Phase II ifetroban programs, to gauge longer-term impact.

Key Terms

non-steroidal anti-inflammatory drugs (NSAIDs), coronary artery bypass graft (CABG), j-code reimbursement, phase ii, +4 more

8 terms

non-steroidal anti-inflammatory drugs (NSAIDs) medical

"known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs)"

Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of medicines that reduce pain, fever and swelling without using steroid hormones, commonly used for headaches, muscle aches and arthritis. For investors, NSAIDs matter because they are a large, widely prescribed product category whose sales, patent status, safety signals or regulatory actions can affect drug makers’ revenues and costs; think of them as a steady-income product line that can be disrupted by recalls, new competition or safety news.

coronary artery bypass graft (CABG) medical

"contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery"

A coronary artery bypass graft (CABG) is a surgical procedure that restores blood flow to the heart by using a blood vessel taken from elsewhere in the body to create a new route around blocked coronary arteries — like rerouting traffic around a closed road. Investors care because CABG volumes, outcomes and costs influence hospital revenue, medical device and drug demand, insurance payouts, and regulatory or reimbursement decisions in the cardiovascular sector.

j-code reimbursement regulatory

"information on safety, dosing, efficacy, and access with J-Code reimbursement support"

J-code reimbursement is the payment system insurers use to cover injectable or infused drugs given by a clinician, where each drug is billed with a specific J-code (like a barcode for medicines) and paid according to a set schedule. Investors care because this determines how reliably and how much a healthcare provider or drug maker will be paid for those treatments, affecting revenue predictability, pricing power, and patient access.

phase ii medical

"Phase II clinical programs underway evaluating its ifetroban product candidate"

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

idiopathic pulmonary fibrosis medical

"ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

duchenne muscular dystrophy medical

"ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

systemic sclerosis medical

"ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis"

Systemic sclerosis is a chronic autoimmune disease where the body's repair system overreacts, causing hardening and tightening of skin and internal organs much like scar tissue spreading beyond a wound. It matters to investors because it creates a clear medical need for new treatments, influences the size and urgency of clinical trials, and affects regulatory scrutiny, pricing power, and long-term healthcare costs tied to any therapy or diagnostic that proves effective.

h. pylori medical

"Talicia oral capsule, for the treatment of H. pylori infection"

A common stomach bacterium that can live in the lining of the stomach and upper intestine, often causing chronic inflammation, sores (ulcers), and increasing the risk of stomach cancer. For investors, H. pylori matters because testing, treatments and vaccines create ongoing markets for diagnostics, pharmaceuticals and public-health programs, and shifts in infection rates, drug resistance or new therapies can change revenue and regulatory risk for companies in those areas.

AI-generated analysis. Not financial advice.

A Safe and Effective Non-Opioid Pain Management Solution

NASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor^® (ibuprofen) Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management.  

With this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months and older for:

• Management of mild to moderate pain, including postoperative pain
• Management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics
• Reduction of fever

This expanded labeling reinforces Caldolor's role as a versatile, non-opioid intravenous analgesic option for use in perioperative and acute care settings.

Advancing Perioperative Pain Management

The newly launched Caldolor website aligns with this expanded indication, featuring dedicated content on postoperative pain management and the importance of multimodal, opioid-sparing approaches.

Postoperative pain remains a significant challenge across surgical setting, with a growing emphasis on reducing opioid exposure while maintaining effective pain control. The updated website provides healthcare professionals with resources that focus on:

• The role of IV non-opioid options like Caldolor in perioperative care
• Strategies to support opioid stewardship amid the ongoing opioid crisis
• Clinical data supporting safe and effective pain and fever management with Caldolor

In addition to featuring the new postoperative pain indication, the website offers comprehensive information on safety, dosing, efficacy, and access with J-Code reimbursement support.

The site reinforces Caldolor as "A Safe and Effective Non-Opioid Pain Management Solution."

Healthcare professionals can explore the updated website and resources at www.caldolor.com, which includes full prescribing and safety information.

For medical inquiries, contact MSLsupport@cumberlandpharma.com. For product access support, contact orders@cumberlandpharma.com.

About Caldolor^® (ibuprofen) Injection
Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain, including postoperative pain management, as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) and patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com.

About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes:

• Acetadote^® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
• Caldolor^® (ibuprofen) injection, for the treatment of pain and fever;
• Kristalose^® (lactulose) oral, a prescription laxative, for the treatment of constipation;
• Sancuso^® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
• Vaprisol^® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
• Vibativ^® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and
• Talicia^®(omeprazole magnesium, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection.

The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis.

For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website www.cumberlandpharma.com.

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-expanded-indication-for-caldolor-ibuprofen-injection--and-launch-of-new-brand-website-302744319.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

What did Cumberland (CPIX) announce on April 16, 2026 about Caldolor?

They announced FDA approval expanding Caldolor's indication to include postoperative pain for adults and children three months and older. According to the company, the update also coincides with a new healthcare professional website and J-Code reimbursement support.

How does the new Caldolor indication affect pediatric use for CPIX?

The approval covers pediatric patients ages 3 months and older for pain and fever management. According to the company, Caldolor is now indicated for postoperative pain management in both adult and pediatric perioperative settings.

Does the Caldolor update change reimbursement or access for hospitals (CPIX)?

The company highlights J-Code reimbursement support and access resources on the new website to aid hospitals. According to the company, the site offers dosing, safety, and access information for perioperative use and formulary discussions.

Are there safety limits for Caldolor after the April 2026 approval (CPIX)?

Yes. Caldolor remains contraindicated in patients with NSAID hypersensitivity and during the peri-operative period of CABG surgery. According to the company, full prescribing information and boxed warnings are provided on the website.

Can Caldolor be used alone for moderate to severe postoperative pain (CPIX)?

For moderate to severe pain, Caldolor is indicated as an adjunct to opioid analgesics, not necessarily as sole therapy. According to the company, it supports multimodal, opioid-sparing perioperative strategies.

Where can healthcare professionals find Caldolor prescribing and perioperative resources (CPIX)?

Healthcare professionals can access the redesigned resource site at www.caldolor.com for full prescribing, dosing, safety, and perioperative guidance. According to the company, the site was launched alongside the expanded postoperative indication.